Product Information
ORILISSA 150 MG TABLET is a brand product labeled by AbbVie Inc., priced at $43.8087 per EA under NDC 00074003828. Its NADAC has been published 402 times since Jan 23, 2019.
FDA first approved this application on Jul 23, 2018.
Strength
150 mg/1
Manufacturer
AbbVie Inc.NDC
00074003828
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ELAGOLIX SODIUMApproval Type
New Drug (NDA)
FDA Application
NDA210450FDA Approved
7/23/2018
On Market Since
7/23/2018
Pharmacological Classes
Price Statistics
The NADAC for ORILISSA 150 MG TABLET has been published 402 times since Jan 23, 2019, and over the history we have for it it has risen 49.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $43.8087 per EA |
|---|---|
| All-time high | $43.8196 (Sep 16, 2026) |
| All-time low | $28.9809 (Nov 20, 2019) |
| 52-week high | $43.8196 |
| 52-week low | $41.7051 |
| Median price | $36.1525 |
| Average price | $36.4440 |
| Largest weekly change | +7.4% (Jan 8, 2020) |
| Weeks tracked | 402 |
| Tracking since | Jan 23, 2019 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Elagolix market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
AbbVie Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Elagolix market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Gonadotropin Releasing Hormone Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ORILISSA 150 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ORILISSA 150 MG TABLET, manufactured by AbbVie Inc., is $43.8087 per EA (NDC 00074003828), effective Sep 30, 2026.
How has the price of ORILISSA 150 MG TABLET changed over time?
Over the history we have for it, the NADAC for ORILISSA 150 MG TABLET has risen 49.4%. It has been tracked across 402 weekly CMS publications since Jan 23, 2019.
What are the highest and lowest recorded NADAC prices for ORILISSA 150 MG TABLET?
Since Jan 23, 2019, the NADAC for ORILISSA 150 MG TABLET has ranged from a low of $28.9809 (Nov 20, 2019) to a high of $43.8196 (Sep 16, 2026), with a median of $36.1525 per EA.
Are there cheaper alternatives to ORILISSA 150 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of ORILISSA 150 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ORILISSA 150 MG TABLET?
ORILISSA 150 MG TABLET (NDC 00074003828) is labeled by AbbVie Inc., and CMS classifies it as a brand product.